Comment on Media Report
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
德國漢堡/ACCESSWIRE /2024年11月14日/Evotec SE（法蘭克福證券交易所代碼：EVT）（SDAX/TecDAX，Prime Standard，ISIN：DE 000 566480 9，WKN 566480（納斯達克股票代碼：EVO）關於媒體報道，Evotec SE（「公司」）宣佈已收到美國上市生物技術公司Halo的非約束性意向書，未經事先聯繫 Zyme Therapeutics Inc. 關於向公司股東提出的收購要約，要約價爲每股11.00歐元。公司將仔細分析這種意向書，決定下一步行動，並根據法律要求向資本市場通報情況。
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com
聯繫人：Volker Braun，德國漢堡 Essener Bogen 7 曼弗雷德·艾根校區 Evotec SE 全球投資者關係與環境、社會及管治執行副總裁，電話：+49 (0) 151 1940 5058 (m)，volker.braun@evotec.com
SOURCE: Evotec SE
來源：Evotec SE
